Patents Assigned to Array Biopharma Inc.
  • METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS
    Publication number: 20140194403
    Abstract: Provided herein are methods for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal, which comprises administering to said mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.
    Type: Application
    Filed: July 16, 2013
    Publication date: July 10, 2014
    Applicant: Array BioPharma Inc.
    Inventors: Julia Haas, Steven W. Andrews, Yutong Jiang, Gan Zhang
  • Pyrrolopyridines as kinase inhibitors
    Patent number: 8758830
    Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: June 24, 2014
    Assignee: Array BioPharma, Inc.
    Inventors: Yvan Le Huerou, James F. Blake, Indrani W. Gunawardana, Peter J. Mohr, Eli M. Wallace, Bin Wang, Mark Joseph Chicarelli, Michael Lyon
  • Piperidinyl-substituted lactams as GPR119 modulators
    Patent number: 8754226
    Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which X1, X2, L, R3, R4, R5, R6, R6a, R7, R9, R9a, and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: June 17, 2014
    Assignee: Array BioPharma Inc.
    Inventors: Thomas Daniel Aicher, Josef Roland Bencsik, Kevin Ronald Condroski, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Scott Alan Pratt, Ajay Singh, Timothy M. Turner, David A. Mareska, Steven Armen Boyd
  • AKT PROTEIN KINASE INHIBITORS
    Publication number: 20140148436
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: Array BioPharma, Inc.
    Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicolas C. Kallan, Mark Munson, Guy P.A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
  • Substituted Benzoazepines as Toll-Like Receptor Modulators
    Publication number: 20140142086
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: September 3, 2013
    Publication date: May 22, 2014
    Applicants: ARRAY BIOPHARMA, INC., VENTIRX PHARMACEUTICALS, INC.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert M. Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR
    Publication number: 20140128442
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Application
    Filed: October 18, 2013
    Publication date: May 8, 2014
    Applicants: Array BioPharma, Inc., Novartis AG
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • 6-substituted phenoxychroman carboxylic acid derivatives
    Patent number: 8716498
    Abstract: A compound having the formula: is useful in the preparation of compounds of Formula I.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: May 6, 2014
    Assignee: Array Biopharma, Inc.
    Inventors: Laurence E. Burgess, Christopher T. Clark, Adam Cook, Christopher P. Corrette, Robert Kirk DeLisle, George A. Doherty, Kevin W. Hunt, Todd T. Romoff, Ganghyeok Kim
  • Serine/threonine kinase inhibitors
    Patent number: 8697715
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: April 15, 2014
    Assignees: Array BioPharma, Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • PYRROLOPYRIDINES AS KINASE INHIBITORS
    Publication number: 20140100369
    Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 23, 2013
    Publication date: April 10, 2014
    Applicant: Array BioPharma Inc.
    Inventors: Yvan Le Huerou, James F. Blake, Indrani W. Gunawardana, Peter J. Mohr, Eli M. Wallace, Bin Wang, Mark Joseph Chicarelli, Michael Lyon
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 8691809
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: April 8, 2014
    Assignees: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong Woon Yang
  • MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20140094603
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 3, 2014
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen R. Laird, John Robinson, Shelley Allen
  • Substituted Benzoazepines As Toll-Like Receptor Modulators
    Publication number: 20140088085
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.
    Type: Application
    Filed: January 12, 2012
    Publication date: March 27, 2014
    Applicants: ARRAY BIOPHARMA, INC, VENTIRX PHARMACEUTICALS, INC
    Inventors: Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones, James Jeffry Howbert, Robert Hershberg, Joseph P. Lyssikatos, Hong Woon Yang
  • AKT protein kinase inhibitors
    Patent number: 8680114
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: March 25, 2014
    Assignees: Array Biopharma, Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicholas C. Kallan, Mark Munson, Guy P. A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
  • PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20140080829
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: November 21, 2013
    Publication date: March 20, 2014
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
  • Aminodiazepines as toll-like receptor modulators
    Patent number: 8673898
    Abstract: Provided are compositions and methods useful for modulation signaling through the Toll-like receptor TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: March 18, 2014
    Assignee: Array BioPharma Inc.
    Inventors: George A. Doherty, Zachary Jones
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20140066453
    Abstract: Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Application
    Filed: August 27, 2013
    Publication date: March 6, 2014
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: Jim Blake, Huifen Chen, Mark Chicarelli, John Gaudino, Lewis Gazzard, Sam Kintz, Pete Mohr, Kirk Robarge, Jacob Schwarz, Aihe Zhou
  • TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS
    Publication number: 20140045835
    Abstract: Provided herein are methods of treating diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases by administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 13, 2014
    Applicant: Array BioPharma Inc.
    Inventors: Shelley Allen, Robert Kirk DeLisle, Julie Marie Hicks, Erik James Hicken, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, John E. Robinson, Qian Zhao
  • TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS
    Publication number: 20140045817
    Abstract: Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: Array BioPharma Inc.
    Inventors: Shelley Allen, Laura L. Celeste, T. Gregg Davis, Robert Kirk DeLisle, Julie Marie Hicks, Stefan D. Gross, Erik James Hicken, Leila J. Jackson, Nicholas C. Kallan, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, Jed Pheneger, Bryson Rast, John E. Robinson, Stephen T. Schlachter, George T. Topalov, A. Dale Wright, Qian Zhao
  • N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
    Patent number: 8648087
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: February 11, 2014
    Assignee: Array Biopharma, Inc.
    Inventors: Joseph P. Lyssikatos, Julie Marie Greschuk, Fredrik P. Marmsäter, Qian Zhao, D. David Hennings, Weidong Liu
  • N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
    Publication number: 20140023643
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Application
    Filed: September 23, 2013
    Publication date: January 23, 2014
    Applicant: ARRAY BIOPHARMA, INC.
    Inventors: Joseph P. LYSSIKATOS, Julie Marie GRESCHUK, Fredrik P. MARMSATER, Qian ZHAO, D. David HENNINGS, Weidong LIU